Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy

S Broomfield, A Currie, RG van der Most, M Brown… - Cancer research, 2005 - AACR
S Broomfield, A Currie, RG van der Most, M Brown, I Van Bruggen, BWS Robinson, RA Lake
Cancer research, 2005AACR
Resection alone is rarely curative for advanced tumors, but the outcome generally improves
with adjuvant therapy. We have previously shown that a combination of traditional
chemotherapy (gemcitabine) and immunotherapy (anti-CD40/FGK-45) without surgery is
synergistic and can lead to long-term cure when applied to small tumors. Such cured
animals have immunologic memory and are protected from rechallenge. Here we
investigate the effectiveness of combination chemotherapy and immunotherapy after partial …
Abstract
Resection alone is rarely curative for advanced tumors, but the outcome generally improves with adjuvant therapy. We have previously shown that a combination of traditional chemotherapy (gemcitabine) and immunotherapy (anti-CD40/FGK-45) without surgery is synergistic and can lead to long-term cure when applied to small tumors. Such cured animals have immunologic memory and are protected from rechallenge. Here we investigate the effectiveness of combination chemotherapy and immunotherapy after partial or complete surgical debulking of large tumors. We found that complete resection followed by combination chemotherapy/immunotherapy led to a high rate of cure (>80%) but failed to induce a long-term, tumor-specific memory. Partial debulking followed by combination therapy elicited the same proportion of cured animals but in contrast to complete resection, a memory response was invoked. We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory.
AACR